Exploring nonreplacement therapies’ impact on hemophilia and other rare bleeding disorders
Authors:
Open Access
- 7 May 2024
- journal article
- review article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (4) , 102434
Abstract
No abstract availableKeywords
Funding Information
- Governo Italiano Ministero dell'Istruzione dell'Università e della Ricerca
This publication has 82 references indexed in Scilit:
- Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System dataJournal of Thrombosis and Haemostasis, 2024
- Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adultsResearch and Practice in Thrombosis and Haemostasis, 2023
- Concizumab: First ApprovalDrugs, 2023
- Hemophilia treatment innovation: 50 years of progress and more to comeJournal of Thrombosis and Haemostasis, 2023
- Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021Journal of Thrombosis and Haemostasis, 2023
- Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiencyBlood Reviews, 2021
- The potential role of emicizumab prophylaxis in severe von Willebrand diseaseBlood Cells, Molecules, and Diseases, 2021
- Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on ConcizumabDrugs, 2018
- Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administrationEuropean Journal of Pharmaceutical Sciences, 2014
- Designing Chemically Modified Oligonucleotides for Targeted Gene SilencingChemistry & Biology, 2012